AI Terminal
STRATEC SE
Notice of Dividend Amount • Apr 11, 2016
416_rns_2016-04-11_5662a9ad-1859-48cd-a5fb-0c579702e0e5.html
Notice of Dividend Amount
Open in ViewerOpens in native device viewer
News Details
Corporate | 11 April 2016 14:23
STRATEC proposes increase of dividend to EUR 0.75 per share
DGAP-News: STRATEC Biomedical AG / Key word(s): Dividend
2016-04-11 / 14:23
The issuer is solely responsible for the content of this announcement.
STRATEC proposes increase of dividend to EUR 0.75 per share
Birkenfeld, April 11, 2016
The Board of Management and Supervisory Board of STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) at their meeting held today approved the recommendation submitted by the Board of Management to propose the payment of a dividend of EUR 0.75 per share for the 2015 financial year for approval by the Annual General Meeting on June 9, 2016 (distribution in previous year: EUR 0.70 per share). Based on the current total of 11,846,280 shares with dividend entitlement, the proposal corresponds to a 7.7% increase in the distribution total to EUR 8.885 million (previous year: EUR 8.248 million). STRATEC continues to follow its shareholder-friendly and continuity-based dividend policy. If approved, this year’s dividend would be the twelfth consecutive increase in the distribution to shareholders since dividends were first paid in 2004.
Based on preliminary figures announced on March 15, 2016, STRATEC Biomedical AG increased its sales by 1.4% to EUR 146.9 million in the 2015 financial year. The EBIT margin rose significantly from 16.6% in the previous year to 18.3%. The final audited results for the 2015 financial year will be published on April 14, 2016.
About STRATEC
STRATEC Biomedical AG ( www.stratec.com ) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
2016-04-11 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | STRATEC Biomedical AG |
| Gewerbestr. 37 | |
| 75217 Birkenfeld | |
| Germany | |
| Phone: | +49 (0)7082 7916 0 |
| Fax: | +49 (0)7082 7916 999 |
| E-mail: | [email protected] |
| Internet: | www.stratec.com |
| ISIN: | DE000STRA555 |
| WKN: | STRA55 |
| Indices: | TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX |
| End of News | DGAP News Service |